SEMA7A-ITGB1 axis plays pivotal roles for EGFR-TKI resistance in human EGFR mutant lung cancer

被引：0
|
作者：
Kinehara, Yuhei [1 ,2 ]
Nagatomo, Izumi [1 ]
Kijima, Takashi [3 ]
Kumanogoh, Atsushi [1 ]
机构：
[1] Osaka Univ, Dept Resp Med Immunol, Suita, Osaka, Japan
[2] Hosp Nissay, Osaka, Japan
[3] Hyogo Coll Med, Div Resp Med, Nishinomiya, Hyogo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-3044
引用
收藏
页码：1185 / 1185
页数：1
相关论文
共 50 条
  • [31] A novel strategy of EGFR-TKI combined chemotherapy in the treatment of human lung cancer with EGFR-sensitive mutation
    Zhang, Lanlin
    Qi, Yuan
    Xing, Kailin
    Qian, Song
    Zhang, Ping
    Wu, Xianghua
    ONCOLOGY REPORTS, 2018, 40 (02) : 1046 - 1054
  • [32] Relation of the BIM deletion polymorphism to intrinsic EGFR-TKI resistance of Chinese patients with EGFR mutant advanced non-small cell lung cancer
    Xin, Shuang
    Zhao, YuanYuan
    Ma, Yuxiang
    Wang, Xueding
    Huang, Yan
    Zhao, Hongyun
    Zhu, Chen
    Yang, Yunpeng
    Zhang, Li
    Huang, Min
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR-TKI resistance in EGFR mutant non-small cell lung cancer
    Chen, Junjie
    Shi, Lin
    Qian, Yao
    Jin, Yi
    Dong, Nian
    Chen, Chengshui
    Wang, Beibei
    JOURNAL OF THORACIC DISEASE, 2023, 15 (06) : 3359 - +
  • [34] Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer
    Zhang, Chen
    Cao, Honggang
    Cui, Yanan
    Jin, Shidai
    Gao, Wen
    Huang, Chenjun
    Guo, Renhua
    THORACIC CANCER, 2021, 12 (19) : 2574 - 2584
  • [35] Serial ctDNA Assessment of Response and Resistance to EGFR-TKI for Patients with EGFR-L858R Mutant Lung Cancer from a Prospective Trial
    Zhou, Qing
    Yang, Jin-Ji
    Chen, Zhi-Hong
    Zhang, Xu-Chao
    Yan, Hong-Hong
    Su, Jian
    Chen, Hua-Jun
    Xu, Chong-Rui
    Tu, Hai-Yan
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S359 - S359
  • [36] Deciphering the Dynamics of EGFR-TKI Resistance in Lung Cancer: Insights from Bibliometric Analysis
    Zhou, Yinxue
    Wu, Tingyu
    Sun, Jiaxing
    Bi, Huanhuan
    Xiao, Yuting
    Shao, Yanmei
    Han, Weizhong
    Wang, Hongmei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 4327 - 4343
  • [37] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [38] Consensus on the lung cancer management after third-generation EGFR-TKI resistance
    Zhou, Qing
    Zhao, Hongyun
    Lu, Shun
    Cheng, Ying
    Liu, Ying
    Zhao, Mingfang
    Yu, Zhuang
    Hu, Chengping
    Zhang, Li
    Yang, Fan
    Zhao, Jun
    Guo, Renhua
    Ma, Rui
    Du, Yingying
    Dong, Xiaorong
    Cui, Jiuwei
    Tan, Daniel S. W.
    Ahn, Myung-Ju
    Tsuboi, Masahiro
    Liu, Si-Yang Maggie
    Mok, Tony S.
    Wu, Yi-Long
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 53
  • [39] Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
    Lee, Po-Hsin
    Huang, Yen-Hsiang
    Lin, Ho
    Hsu, Kuo-Hsuan
    Chen, Kun-Chieh
    Tseng, Jeng-Sen
    Chang, Gee-Chen
    Yang, Tsung-Ying
    MEDICINA-LITHUANIA, 2022, 58 (07):
  • [40] Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer
    Fu, Yulong
    Zhang, Yang
    Lei, Zhe
    Liu, Ting
    Cai, Tingting
    Wang, Anqi
    Du, Wenwen
    Zeng, Yuanyuan
    Zhu, Jianjie
    Liu, Zeyi
    Huang, Jian-an
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
12345